Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oral anti-coagulant

PreclinicalSmall molecule

MManimarane Arjunan, MD,DM (Cardiology)

Oral anti-coagulant is one of 2 small molecule programs targeting Coronavirus Disease 2019. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronavirus Disease 2019Completed

Coronavirus Disease 2019Preclinical

Completed

Competition

Competitive Landscape

1 competitor in Coronavirus Disease 2019

#DrugCompanyPhaseTrials

Huashi Baidu Granule

XXiyuan Hospital of China Academy of Chinese Medical Sciences

Oral anti-coagulant

MManimarane Arjunan, MD,DM (Cardiology)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Coronavirus Disease 20191 trial

C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.

Completed·MManimarane Arjunan, MD,DM (Cardiology)·N/A·NCT04935515·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oral anti-coagulant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral anti-coagulant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral anti-coagulant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Manimarane Arjunan, MD,DM (Cardiology) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MManimarane Arjunan, MD,DM (Cardiology)

Related News